Exhibit 99.1 Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates ~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in Second-Line Advanced Non-Small Cell Lung Cancer SAN CARLOS, Calif., February 24, 2026 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on ...

Core Insights - Iovance Biotherapeutics announced positive early data from a pilot clinical trial of lifileucel, showing a 50% Objective Response Rate (ORR) in patients with advanced undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) who were refractory to prior therapies [1][2] Company Overview - Iovance Biotherapeutics focuses on developing novel tumor infiltrating lymphocyte (TIL) therapies for cancer patients, aiming to be a leader in this field [5] - The company has demonstrated promising clinical data across multiple solid tumors and is committed to continuous innovation in cell therapy [5] Clinical Trial Results - Among the first six evaluable patients treated with lifileucel, the confirmed ORR was 50%, with patients showing deep responses that improved over time [2] - The mean sum of diameters of tumors at baseline was 117 millimeters, and patients had undergone more than two prior lines of therapy [2] - The safety profile of lifileucel was favorable and consistent with its use in other indications [2] Market Opportunity - There are over 8,000 patients diagnosed annually with UPS and DDLPS in the U.S. and Europe, highlighting a significant market opportunity [1] - UPS and DDLPS are aggressive sarcomas with poor prognosis, affecting more than 3,000 patients in the U.S. and over 5,000 in Europe each year [3] Unmet Medical Need - Current treatment options for second-line patients are limited, with recent studies reporting ORRs of less than 5% and median overall survival of approximately 9-10 months [3] - Lifileucel has the potential to address this unmet need, as there are currently no approved immunotherapy options for these patients [4] Future Plans - Iovance plans to initiate a single-arm registrational trial for lifileucel in second-line advanced UPS and DDLPS in Q2 2026 and will engage with the FDA for expedited approval [2] - The company also aims to explore lifileucel in other high-grade soft tissue sarcoma subtypes with high unmet need [2]

~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in Second-Line Advanced Non-Small Cell Lung Cancer SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer ...

Corporate Overview February 2026 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. 1 Forward-Looking Statements Certain matters discussed in this presentation are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Without limiting the foregoing, we may, in some cases, use terms such as "predicts," "believes," "potentia ...

Core Viewpoint - Iovance Biotherapeutics is positioned for significant growth due to its recent product approval and ongoing studies across multiple cancer indications, making it an attractive investment opportunity in the biotech sector [4][10]. Company Overview - Iovance Biotherapeutics has achieved approval for its first product, lifileucel, commercialized as Amtagvi, which targets melanoma that cannot be completely removed by surgery or has metastasized [4]. - The company has a market capitalization of $1.1 billion, with current stock trading at $2.87 [5][6]. Financial Performance - Iovance is not yet profitable, which is typical for biotech firms at this stage, but it reported a 13% increase in revenue to $68 million in the latest quarter [7]. - The stock has shown a price range of $1.64 to $5.88 over the past 52 weeks, indicating volatility and potential for growth [6]. Product and Treatment Efficacy - Amtagvi is a tumor-infiltrating lymphocyte (TIL) treatment that reinvigorates a patient's own TIL to combat cancer cells [6]. - A recent study indicated a 52% objective response rate for Amtagvi in real-world conditions, surpassing the 31% response rate from the clinical trial that led to its accelerated approval [8]. Pipeline and Future Prospects - Iovance is exploring lifileucel for various cancer types and in combination with other treatments, with many trials currently in phase 2, suggesting potential for additional indications soon [9]. - The stock is accessible for investors at under $3, with the potential for significant appreciation if the pipeline proves successful [10].

Core Viewpoint - ImmunityBio's stock surged 41.86% following the European Commission's conditional marketing authorization for its immunotherapy Anktiva to treat bladder cancer, indicating strong market interest and potential for growth in sales [1][3]. Company Summary - ImmunityBio develops immunotherapies and vaccines for cancers and infectious diseases, with Anktiva being its flagship product [1]. - The company went public in 2015 and has seen its stock price decline by 75% since then, despite recent gains [1]. - Anktiva is now authorized for use in over 30 new countries, which is expected to accelerate sales growth [3]. - The company reported a 700% increase in Anktiva sales in 2025 and has received additional approvals from the Saudi Food and Drug Authority [7]. Market Performance - ImmunityBio's stock closed at $8.54 with a trading volume of 78.5 million shares, significantly above its three-month average of 28.2 million shares [1]. - The S&P 500 and Nasdaq Composite also saw gains, with increases of 0.53% and 0.78% respectively on the same day [2]. Investment Considerations - Despite the promising developments with Anktiva, ImmunityBio remains a volatile stock, heavily reliant on positive news regarding its main immunotherapy [4]. - Analysts from The Motley Fool Stock Advisor have not included ImmunityBio in their list of top investment recommendations, suggesting caution for potential investors [5].

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

Core Viewpoint - Iovance Biotherapeutics, Inc. will host a conference call and live audio webcast on February 24, 2026, to report its fourth quarter and full year 2025 financial results and corporate updates [1]. Company Overview - Iovance Biotherapeutics, Inc. focuses on innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for cancer patients, aiming to be a global leader in this field [3]. - The company is pioneering a transformational approach to cancer treatment by utilizing the human immune system to recognize and destroy diverse cancer cells [3]. - Iovance's TIL platform has shown promising clinical data across multiple solid tumors, and its product Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication [3]. - The company is committed to continuous innovation in cell therapy, including gene-edited cell therapy, to improve the lives of cancer patients [3].

Core Insights - Iovance Biotherapeutics, Inc. announced best-in-class data for its commercial TIL therapy, Amtagvi (lifileucel), showing unprecedented response rates in advanced melanoma patients [1][3] Group 1: Clinical Data - In a real-world study, 41 evaluable patients with advanced melanoma treated with Amtagvi showed a confirmed objective response rate (ORR) of 44% and a disease control rate of 73% [3] - The ORR was significantly higher at 52% for patients who had received two or fewer prior lines of therapy, compared to 33% for those with three or more lines [3] - These real-world response rates surpass the 31% ORR observed in the C-144-01 clinical trial that led to the FDA's accelerated approval of Amtagvi [3] Group 2: Expert Commentary - Dr. Lilit Karapetyan emphasized the importance of early treatment with lifileucel, noting the potential for more patients to benefit as TIL therapy adoption increases [4] - Daniel Kirby, Chief Commercial Officer of Iovance, highlighted the impressive response rates and five-year durability data, reinforcing Amtagvi's best-in-class profile [4] Group 3: Market Context - Advanced melanoma represents a significant unmet medical need, with over 8,000 annual deaths in the U.S. and more than half of first-line treatment patients progressing within 12 months [4] - The FDA granted accelerated approval for Amtagvi in February 2024 based on its ORR and duration of response from the C-144-01 trial [4] Group 4: Ongoing Research - Iovance is conducting the TILVANCE-301 Phase 3 clinical trial in frontline advanced melanoma to further confirm the clinical benefits of Amtagvi [4]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgent need for energy to support its growth [1][2][3] Investment Opportunity - A specific company, largely overlooked by AI investors, is positioned to benefit from the increasing demand for energy due to AI data centers, making it a critical player in the upcoming AI energy spike [3][6] - This company is not a chipmaker or cloud platform but owns essential energy infrastructure assets that are vital for the future of AI [3][7] Energy Demand and Infrastructure - AI technology is extremely energy-intensive, with data centers consuming as much energy as small cities, leading to concerns about power grid strain and rising electricity prices [2][4] - The company is involved in nuclear energy infrastructure, which is crucial for America's next-generation power strategy, and is capable of executing large-scale engineering, procurement, and construction projects across various energy sectors [7][8] Financial Position - The company is debt-free and has a significant cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened with debt [8][10] - It also holds a substantial equity stake in another AI-related company, providing investors with indirect exposure to multiple growth engines without the associated premium [9][10] Market Trends - The current market environment is characterized by a surge in U.S. LNG exports and a focus on onshoring due to tariffs, which the company is well-positioned to capitalize on [5][14] - The influx of talent into the AI sector ensures continuous innovation and advancements, reinforcing the importance of investing in AI-related companies [12][13] Conclusion - The company represents a unique investment opportunity in the intersection of AI and energy, with potential for significant returns as the demand for energy in AI applications continues to grow [10][15]